<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207736</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-AC-017</org_study_id>
    <nct_id>NCT04207736</nct_id>
  </id_info>
  <brief_title>The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.</brief_title>
  <official_title>The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Vehicle-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial&#xD;
      to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Vehicle-controlled Phase&#xD;
      3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%)&#xD;
      Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental&#xD;
      Exposure Chamber (EEC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Actual">February 16, 2021</completion_date>
  <primary_completion_date type="Actual">February 16, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular itching evaluated by the Subject.</measure>
    <time_frame>During EEC allergen exposure.</time_frame>
    <description>The method of assessment for the primary outcome is a 9-point ocular itch scale (0 none - 4 severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness evaluated by the Subject.</measure>
    <time_frame>During EEC allergen exposure.</time_frame>
    <description>The method of assessment for the key secondary outcome is a 9-point ocular redness scale (0 none -4 extremely sever).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.25%)</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ophthalmic Solution</intervention_name>
    <description>Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.</description>
    <arm_group_label>Vehicle Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  be at least 18 years of age of either gender and any race&#xD;
&#xD;
          -  have at least a two-year history of moderate-to-severe ragweed-induced allergic&#xD;
             conjunctivitis based on principal investigator's judgement&#xD;
&#xD;
          -  have a positive skin prick test to ragweed pollen within the past year of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known contraindication or hypersensitivities to any components of the investigational&#xD;
             product medication or components&#xD;
&#xD;
          -  history of uveitis, blepharitis, dry eye syndrome, herpes simplex keratitis, or herpes&#xD;
             zoster keratitis;&#xD;
&#xD;
          -  presence of any ocular infection (bacterial, viral, or fungal) or active ocular&#xD;
             inflammation (e.g., follicular conjunctivitis, allergic conjunctivitis) within 14 days&#xD;
             prior to screening&#xD;
&#xD;
          -  presence of any chronic ocular degenerative condition or ocular inflammation that, in&#xD;
             the opinion of the investigator, is likely to worsen over the course of the clinical&#xD;
             trial;&#xD;
&#xD;
          -  diagnosis of moderate-to-severe pinguecula or pterygium (particularly if it results in&#xD;
             chronic erythema), Stevens-Johnson Syndrome, ocular cicatricial pemphigoid, mucous&#xD;
             membrane pemphigoid, significant conjunctival scarring, chemical burn, herpetic or&#xD;
             neurotrophic keratitis, Cryopyrin Associated Periodic Syndrome (CAPS), or keratoconus&#xD;
&#xD;
          -  woman of childbearing potential who is pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cliantha Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reproxalap</keyword>
  <keyword>INVIGORATE</keyword>
  <keyword>ADX-102</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

